ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / WST / earnings
DXCM (79) RMD (80) MDLN (45) BDX (67) ⌘ Pro Terminal →

West Pharmaceutical Services Inc. (WST) Next Earnings Date & Expected ±5.1% Move

$407.88 -1.15% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $408.01

West Pharmaceutical Services Inc. (WST) earns a Roarable Rating of A- (Buy) with 81/100 RQD Confidence. High-quality cash engine (35.9% gross margin, 18% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE A- • BUY Cap $28.74B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on WST Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is WST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, West Pharmaceutical Services Inc. (NYSE: WST) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 81/100 at a spot price of $407.88 (-1.15% 1D, market cap $28.74B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, WST ranks #14 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does WST compare to DXCM and RMD in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), WST carries a Roarable A- (81/100 RQD), trailing P/E of 59.4x, gross margin of 35.9%, and ROIC of 17.9%. By comparison, DXCM (DexCom Inc.) holds a B+ grade (79/100 RQD, P/E 36.1x, ROIC 21.6%, cap $30.69B) and RMD (ResMed Inc.) posts a B+ grade (80/100 RQD, P/E 25.4x, ROIC 22.9%, cap $32.34B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for WST?
▼

Per WST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000105770), West Pharmaceutical Services Inc. generated $3.07B in revenue (+6.3% YoY), $493.7M in net income, and $468.9M in free cash flow against $4.27B in total assets and $202.8M in total debt. Key quantitative strengths: Strong cash generator (35.9% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 59x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $408.00 (+0.03%)🧬 Disciplined Float (+0.24% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 15.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 81/100 (A-) historically ranked in the Top 8% of excess returns over the next 90 days (+8.4% avg 90D alpha vs SPY • 71.6% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • A-
025507510081
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk A-
Cash (18)Whales (19)SEC (18)Macro (15)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE+10.4% Base Target
$531 Bull$450 Base$334 Bear
📬 FREE WST RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WST)Realized 20D OHLCV Swing Band: ±5.1%
Deterministic 5-Pillar Attribution (81/100 Composite)
🔍 WHY WST SCORES 81/100 (A-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+19/20 pts (23% of score)

20D Institutional Volume Accumulation (±5.1% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+18/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 15.3% FCF Margin ($468.9M FCF) & 35.9% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)

Disciplined Float (+0.24% YoY Shares) & executive Form 4 sales trim 9 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
73
Grade B$374.65+5% Next Q
Q2 (-2Q)
76
Grade B+$393.48+2.6% Next Q
Q3 (-1Q)
78
Grade A-$403.64+1.1% Next Q
Current
81
Grade A-$407.88+8.4% Hist 90D α
Trajectory: B (73) → A- (81)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the WST Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 81/100 (A-) score, WST faces multiple-compression risk if 59.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 59x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+0.24% YoY Shares) — any gross margin slip below 33.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($371.42) or 200D SMA ($315.66) invalidates the momentum regime and cuts Target Base ($450.10) toward Bear Floor ($334.46).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WST• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “WST Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 81%NO 19%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±5.1% Swing Band

±$20.80 Expected Swing
$387.08 (-5.1%)Spot $407.88$428.68 (+5.1%)
MODEL EARNINGS SETUP GAUGE

WST Quantitative Pre-Earnings Setup: 81/100

Trailing EPS: $7.02 • YoY Revenue Growth: 6.3%

Model Bullish Setup (81/100)Model Risk Weight (19/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$3.07B$493.7M$468.9M35.9%
FY 20242024-12-31$2.89B$492.7M$276.4M34.5%
FY 20232023-12-31$2.95B$593.4M$643.8M35.9%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating WST & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on WST
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
WST // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +35.88%▲ ASCENDING CHANNEL
2026-11-03O $416.7H $416.7L $407.9C $407.9VOL 1.06M
RES: $441.3SUP: $349.4SMA50: $371.4SMA200: $315.7
$450.8$398.9$346.9$295.0$243.1RES $441.3SUP $349.4$407.92026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 WST Butterfly Map → + Track WST →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
41.2%/yr Implied 5Y Growth

vs. +6.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on WST today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →
WST → LLY Confirmed Filing
West Pharmaceutical Services manufactures NovaPure fluoropolymer-coated elastomer plungers and cartridge seals required inside sterile single-dose and multi-dose GLP-1 auto-injector pens.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for WST today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WST)

Health Care Rank #14 of 1015 ⚔️ DXCM vs WST Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WST vs. DXCM, RMD, MDLN, BDX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, West Pharmaceutical Services Inc. (WST) ranks #14 by composite RQD confidence (81/100, grade A-) and #58 by equity capitalization ($28.74B). Within this direct 5-issuer industry benchmark cohort, RMD leads on earnings valuation at 25.4x trailing P/E, while RMD leads on capital efficiency and profitability with 22.9% ROIC and 59.4% gross margin. WST currently leads its immediate peer cohort in composite quantitative strength at 81/100 (A-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
WST ACTIVE
West Pharmaceutical Services Inc.
A- 81/100 59.4x 35.9% 17.9% -1.15% $28.74B Benchmark Subject
DXCM
DexCom Inc.
B+ 79/100 36.1x 60.1% 21.6% +3.00% $30.69B /dxcm-vs-wst →
RMD
ResMed Inc.
B+ 80/100 25.4x 59.4% 22.9% +1.31% $32.34B /rmd-vs-wst →
MDLN
Medline Inc.
D 45/100 — — 8.2% +4.70% $42.23B /mdln-vs-wst →
BDX
Becton Dickinson and Company
C+ 67/100 32.2x 45.4% 4.9% +0.36% $53.90B /bdx-vs-wst →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000105770 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), West Pharmaceutical Services Inc. (WST) reported GAAP revenue of $3.07B (+6.3% vs. FY2024 revenue of $2.89B , and +4.2% cumulative change since FY2023) , GAAP net income of $493.7M, operating cash flow of $754.8M, and free cash flow of $468.9M (+69.6% YoY). On the balance sheet, WST closed FY2025 with $4.27B in total assets against $202.8M in total debt (Altman Z-Score: 19.06, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.07B $493.7M $754.8M $468.9M $4.27B $202.8M
FY2024 (FY) 2024-12-31 $2.89B $492.7M $653.4M $276.4M $3.64B $202.6M
FY2023 (FY) 2023-12-31 $2.95B $593.4M $776.5M $643.8M $16.13B $3.77B

3. WST Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, West Pharmaceutical Services Inc. (NYSE: WST) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 81/100 at a spot price of $407.88 (-1.15% 1D, market cap $28.74B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 19/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, WST ranks #14 in composite RQD confidence.

How does WST compare to DXCM and RMD in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), WST carries a Roarable A- (81/100 RQD), trailing P/E of 59.4x, gross margin of 35.9%, and ROIC of 17.9%. By comparison, DXCM (DexCom Inc.) holds a B+ grade (79/100 RQD, P/E 36.1x, ROIC 21.6%, cap $30.69B) and RMD (ResMed Inc.) posts a B+ grade (80/100 RQD, P/E 25.4x, ROIC 22.9%, cap $32.34B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for WST?

Per WST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000105770), West Pharmaceutical Services Inc. generated $3.07B in revenue (+6.3% YoY), $493.7M in net income, and $468.9M in free cash flow against $4.27B in total assets and $202.8M in total debt. Key quantitative strengths: Strong cash generator (35.9% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 59x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

Where is WST trading relative to its 50-day, 200-day, and 52-week technical levels?

WST last traded at $407.88 (-1.15% on volume of 1,457,555 shares), positioning the stock +9.82% above its 50-day simple moving average ($371.42) and +29.21% above its 200-day simple moving average ($315.66). Across its 52-week range of $223.83 to $438.27, WST sits at the 85.8% percentile with a 14-day RSI of 71.4 (OVERBOUGHT (>70)) and an implied next-earnings move of ±5.1% ($387.08 to $428.68).

Direct Sub-Reports: WST RQD Cockpit WST 12M Forecast WST Earnings & Move WST Dividends & DRIP WST Insiders & 13F WST Whale Options WST Profit Sankey WST News & Why
ROARABLE RATING BRIEF • RQD 81/100 (A-) ✓ SEC XBRL & RQD VERIFIED

WST — West Pharmaceutical Services Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

West Pharmaceutical Services Inc. (WST) earns a live Roarable RQD composite score of 81/100, corresponding to a A- letter grade (Roarable Buy) at a spot price of $407.88 (-1.15% 1D, market capitalization $28.74B).

  • Fundamental Cash Engine (18/20): Anchored by return on invested capital (ROIC) of 17.9%, gross margin of 35.9%, operating margin of 19.0%, and free cash flow yield of 1.60%.
  • Whale 13F & Options Flow (19/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (15/20) + Forensic Balance Sheet (18/20): Incorporates a 1.08x equity beta, Altman Z-Score of 19.06, Piotroski F-Score of 9/9, and Debt/Equity of 0.06x.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry. The company manufactures NovaPure fluoropolymer-coated elastomer plungers and cartridge seals used inside sterile GLP-1 auto-injector pens, positioning it as a component supplier to biopharma drug delivery. — for customer concentration, segment revenue split, or detailed revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), West Pharmaceutical Services Inc. (WST) reported $3.07B in annual revenue (up from $2.89B in FY2024, +6.3% YoY) and $493.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.95B revenue, $593.4M net income) through FY2025, WST scaled operating cash flow to $754.8M and free cash flow to $468.9M, backed by $4.27B in total assets against $202.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (A- • RQD 81/100): Strong cash generator (35.9% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 18/20 and Institutional Whale Flow at 19/20, sustained execution supports upside toward the upper end of the $223.83 – $438.27 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Priced at 59x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 59.4x trailing P/E and 34.7x EV/EBITDA against 19.0% operating margins and a 1.08x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream/downstream: per the graph, WST sits upstream of Eli Lilly (LLY) as a direct supplier. Exposure is described only as "Undisclosed %," so the dependency size cannot be quantified.

Bottlenecks to watch, per the graph:

  • High-Value Product cleanroom molding capacity expansion in Dublin/Waterford.
  • Destocking of inventory by non-GLP-1 pharma customers, creating mixed short-term utilization.

Competing explanation, per the graph: successful commercialization of small-molecule oral GLP-1 pills (e.g., Lilly orforglipron) could reduce long-term per-patient growth in sterile injectable elastomer demand. This is a second-order risk to the tailwind thesis.

  • Key Question #1: Can WST sustain or expand its 19.0% operating margin and 17.9% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.07B and free cash flow of $468.9M, how will capital allocation balance growth reinvestment against $202.8M in total debt?
  • Key Question #3: How sensitive is WST's 55.2x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?

WST Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for West Pharmaceutical Services Inc. (WST) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to WST Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

WST Bull vs. Bear Conversation Board — What's Your Call at $407.88?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON WST 🐻 33% BEARISH CONVICTION
1. Pick Your Side on WST:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $528.15 (+28.0%)
📌 Pinned Debate

Per the RQD rating, 17.9% ROIC, a Piotroski F-Score of 9/9, and Debt/Equity of 0.06 point to a high-return, low-leverage business.

Picked up a starter position in WST in my $100K Virtual Cash book at $412.62. Per the RQD rating, 17.9% ROIC, a Piotroski F-Score of 9/9, and Debt/Equity of 0.06 point to a high-return, low-leverage business.. Trading inside a $223.83–$438.27 52-week range with 1.6% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

RetailWhale_TX 🐂 BULL

Both sides have a point here — WST's 18/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $350.73 (-15.0%)
Spot @ $412.62

Per the market data, a P/E (TTM) of 59.4 and an FCF yield of 1.6% leave little valuation cushion if cash generation disappoints.

Here is the bear case nobody on the bull side wants to address on WST: Per the market data, a P/E (TTM) of 59.4 and an FCF yield of 1.6% leave little valuation cushion if cash generation disappoints.. At 59.4x trailing P/E, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%